Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 16

2332P - Overall survival in breast cancer patients with HER2-low status single- center experience

Date

21 Oct 2023

Session

Poster session 16

Topics

Pathology/Molecular Biology

Tumour Site

Breast Cancer

Presenters

Joanna Huszno

Citation

Annals of Oncology (2023) 34 (suppl_2): S1190-S1201. 10.1016/S0923-7534(23)01928-2

Authors

J. Huszno1, Z. Kolosza2, E. Stobiecka3, D. Ponikiewska3, B. Szcześniak3, J. Simek3, E. Chmielik3

Author affiliations

  • 1 Radiotherapy Department, National Oncology Institute Maria Sklodowskiej-Curie National Research Institute, Gliwice Branch, 44-102 - Gliwice/PL
  • 2 Department Of Biostatistics And Bioinformatics., Maria Sklodowska Curie National Research Institute of Oncology Gliwice Branch, 44-102 - Gliwice/PL
  • 3 Tumor Pathology Department,, National Oncology Institute Maria Sklodowskiej-Curie National Research Institute, Gliwice Branch, 44-102 - Gliwice/PL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2332P

Background

The HER2/neu (ERBB2) oncogene is amplified and/or overexpressed in approximately 15% of breast cancers (BC), and is a strong prognostic factor for relapse and poor overall survival (OS), particularly in node-positive patients. The aim of this study was to evaluate the prognostic significance of HER2-low status in BC. We also compared HER2-low subgroup with HER2-0 according to clinical, histopathological, laboratory and molecular factors.

Methods

The analysis included medical records of 657 BC patients treated in NIO in Gliwice in years 2002-2018. Human epidermal growth factor receptor 2 overexpression was assessed using an IHC method in postoperative specimens or samples obtained by thick needle biopsy. HER2 gene amplification was additionally assessed by FISH in HER2 (2+) cases.

Results

Median age of all women was 52 years (range from 24 to 81). 176 (27%) tumors were HER2-low BC, 248 (38%) HER2-0 and 233 (35%) HER2-positive tumors. There was no difference according to molecular factors such as BRCA gene mutation (p=0.780) or patient’s age (p=0.275) between patients with HER2-low tumors and HER2-0. No differences were also detected between the both groups according to family history of cancer, co-morbid condition, menopausal status, tumor size, lymph nodes with metastases (N+) or higher histologic tumor grade (G3). BC patients with HER2-low tumors more often had positive estrogen receptor status (ER+) (80% vs. 60%, p=0. 0001). There was no reported differences according to OS between patients with HER2-low status and HER2-0 (p=0.747). In subgroup of patients with ER-negative receptor status (ER-) OS were insignificantly worse in patients with HER2-low status in comparison to HER2-0 (5-year OS 72.6% vs. 86.7%, p=0.074). There was also observed tendency to worse OS in patients with HER2-low status in subgroups with higher T3-4 (61.2% vs. 75.1%, p=0.217), G3 (80.7% vs. 89.2%, p=0.139) and N+ (81.3% vs. 86.9%, p=0.599).

Conclusions

There was no association between HER2 status (HER2-low vs. HER2-0) and BRCA gene mutation, tumor size, the presence of metastases in lymph nodes and G. HER2-low status worsens OS in subgroups of patients with negative prognostic factors in comparison to patients with HER2-0.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.